SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) ...

FDA approved to help select patients with metastatic prostate cancer for radioligand therapy before chemotherapy.

Two recent studies from Dr. Sita Kugel’s lab at Fred Hutch Cancer Center identify a key biological signature that not only ...

Surgery and radiation yield similar cancer outcomes for low-risk prostate cancer, but higher-risk cases may require combining treatments, ... Here is a roundup of March 2025 U.S. FDA approvals across ...

PCR-Machines are based on Polymerase Chain Reaction (PCR) and produce copies of genes exponentially. The PCR cycling reactions are carried out in an automated thermocycler, which is capable of ...